213 related articles for article (PubMed ID: 38245572)
1. PRKCSH serves as a potential immunological and prognostic biomarker in pan-cancer.
Wang Q; Wang X; Li J; Yin T; Wang Y; Cheng L
Sci Rep; 2024 Jan; 14(1):1778. PubMed ID: 38245572
[TBL] [Abstract][Full Text] [Related]
2. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
Front Genet; 2022; 13():993438. PubMed ID: 36685895
[No Abstract] [Full Text] [Related]
3. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
4. LncRNA WAC-AS1 expression in human tumors correlates with immune infiltration and affects prognosis.
Wang Y; Gong H; Cao Y
Hereditas; 2023 May; 160(1):26. PubMed ID: 37248547
[TBL] [Abstract][Full Text] [Related]
5. A prognostic and immunological analysis of 7B-containing Kelch structural domain (KLHDC7B) in pan-cancer: a potential target for immunotherapy and survival.
Ding J; Ji X; Liu L; Chen DZ; Luo N; Yu XT; Guo F
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7857-7876. PubMed ID: 37039902
[TBL] [Abstract][Full Text] [Related]
6. XRCC1: a potential prognostic and immunological biomarker in LGG based on systematic pan-cancer analysis.
Wang G; Li Y; Pan R; Yin X; Jia C; She Y; Huang L; Yang G; Chi H; Tian G
Aging (Albany NY); 2024 Jan; 16(1):872-910. PubMed ID: 38217545
[TBL] [Abstract][Full Text] [Related]
7. RecQ mediated genome instability 2 (
Wei W; Ying X; Chen L; Sun Q; Lu X; Xia Y; Xu R; Zhu Z; Zhang D; Tang Q; Li L; Xie J; Yu H
Aging (Albany NY); 2022 May; 14(9):4107-4136. PubMed ID: 35552266
[TBL] [Abstract][Full Text] [Related]
8. Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer.
Huang D; Shen J; Zhai L; Chen H; Fei J; Zhu X; Zhou J
Front Immunol; 2021; 12():812713. PubMed ID: 35069601
[TBL] [Abstract][Full Text] [Related]
9. Pan-cancer analysis reveals correlation between RAB3B expression and tumor heterogeneity, immune microenvironment, and prognosis in multiple cancers.
Liu XS; Chen YL; Chen YX; Wu RM; Tan F; Wang YL; Liu ZY; Gao Y; Pei ZJ
Sci Rep; 2024 Apr; 14(1):9881. PubMed ID: 38688977
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Analysis of
Liu J; Zhu B; Chen J; Cao Y
Anticancer Res; 2023 Oct; 43(10):4491-4509. PubMed ID: 37772558
[TBL] [Abstract][Full Text] [Related]
11. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
12. An Integrated Analysis Identified TAGLN2 As an Oncogene Indicator Related to Prognosis and Immunity in Pan-Cancer.
Pan T; Wang S; Wang Z
J Cancer; 2023; 14(10):1809-1836. PubMed ID: 37476180
[No Abstract] [Full Text] [Related]
13. MCM10, a potential diagnostic, immunological, and prognostic biomarker in pan-cancer.
Chen D; Zhong N; Guo Z; Ji Q; Dong Z; Zheng J; Ma Y; Zhang J; He Y; Song T
Sci Rep; 2023 Oct; 13(1):17701. PubMed ID: 37848534
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
15. A pan-cancer analysis revealing the role of TIGIT in tumor microenvironment.
Wen J; Mao X; Cheng Q; Liu Z; Liu F
Sci Rep; 2021 Nov; 11(1):22502. PubMed ID: 34795387
[TBL] [Abstract][Full Text] [Related]
16. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
Zhang J; Wang K; Hainisayimu T; Li H
Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
[TBL] [Abstract][Full Text] [Related]
17. Navigating PRKCSH's impact on cancer: from N-linked glycosylation to death pathway and anti-tumor immunity.
Cressey R; Han MTT; Khaodee W; Xiyuan G; Qing Y
Front Oncol; 2024; 14():1378694. PubMed ID: 38571496
[TBL] [Abstract][Full Text] [Related]
18. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
[TBL] [Abstract][Full Text] [Related]
19. POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.
Zhao Q; Gao S; Chen X; Zhu X
Aging (Albany NY); 2022 Jun; 14(12):5195-5210. PubMed ID: 35748773
[TBL] [Abstract][Full Text] [Related]
20. Systematic pan-cancer analysis identifies RBM39 as an immunological and prognostic biomarker.
Zhang R; Wang W; Zhang N; Chen X; Liu W; Zhang L; Liu N
J Cell Mol Med; 2022 Sep; 26(18):4859-4871. PubMed ID: 35989423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
